Stayble Therapeutics AB (publ) (STABL.ST)
SEK 0.45
(-5.88%)
SEK 0.45
(-5.88%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -23.73 Million SEK | 2.02% |
| 2022 | -24.22 Million SEK | -101.21% |
| 2021 | -12.04 Million SEK | 24.98% |
| 2020 | -16.04 Million SEK | -102.1% |
| 2019 | -7.94 Million SEK | -29.46% |
| 2018 | -6.13 Million SEK | -118.0% |
| 2017 | -2.81 Million SEK | -133.75% |
| 2016 | -1.2 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.63 Million SEK | 42.21% |
| 2024 Q2 | -3.43 Million SEK | 5.48% |
| 2023 FY | -23.73 Million SEK | 2.02% |
| 2023 Q3 | -7.04 Million SEK | -5.69% |
| 2023 Q1 | -3.71 Million SEK | 22.98% |
| 2023 Q2 | -6.66 Million SEK | -79.24% |
| 2023 Q4 | -6.28 Million SEK | 10.72% |
| 2022 FY | -24.22 Million SEK | -101.21% |
| 2022 Q3 | -5.6 Million SEK | 11.03% |
| 2022 Q2 | -6.3 Million SEK | 15.93% |
| 2022 Q1 | -7.49 Million SEK | -64.37% |
| 2022 Q4 | -4.82 Million SEK | 13.87% |
| 2021 Q1 | -2.05 Million SEK | -88.47% |
| 2021 FY | -12.04 Million SEK | 24.98% |
| 2021 Q3 | -3.01 Million SEK | -22.8% |
| 2021 Q2 | -2.45 Million SEK | -19.28% |
| 2021 Q4 | -4.55 Million SEK | -51.17% |
| 2020 Q1 | -5.4 Million SEK | -50.01% |
| 2020 Q2 | -6.33 Million SEK | -17.22% |
| 2020 Q4 | -1.09 Million SEK | 58.88% |
| 2020 FY | -16.04 Million SEK | -102.1% |
| 2020 Q3 | -2.65 Million SEK | 58.05% |
| 2019 Q2 | -1.22 Million SEK | 32.79% |
| 2019 Q1 | -1.82 Million SEK | -97.01% |
| 2019 Q4 | -3.6 Million SEK | -377.73% |
| 2019 FY | -7.94 Million SEK | -29.46% |
| 2019 Q3 | -754 Thousand SEK | 38.55% |
| 2018 Q4 | -926.6 Thousand SEK | 0.0% |
| 2018 FY | -6.13 Million SEK | -118.0% |
| 2017 FY | -2.81 Million SEK | -133.75% |
| 2016 FY | -1.2 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| NextCell Pharma AB | -41.95 Million SEK | 43.429% |
| Biovica International AB (publ) | -124.82 Million SEK | 80.983% |
| Abliva AB (publ) | -95.5 Million SEK | 75.147% |
| Active Biotech AB (publ) | -45.8 Million SEK | 48.173% |
| Aptahem AB (publ) | -11.11 Million SEK | -113.599% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 90.451% |
| BioInvent International AB (publ) | -330.3 Million SEK | 92.814% |
| BioArctic AB (publ) | 229.24 Million SEK | 110.354% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 58.225% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 94.908% |
| Cantargia AB (publ) | -280.02 Million SEK | 91.523% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -12.546% |
| CombiGene AB (publ) | -35.66 Million SEK | 33.445% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 92.739% |
| Fluicell AB (publ) | -26.55 Million SEK | 10.609% |
| Genovis AB (publ.) | 61.5 Million SEK | 138.597% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 97.146% |
| Mendus AB (publ) | -101.61 Million SEK | 76.641% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 540.717% |
| LIDDS AB (publ) | -40.2 Million SEK | 40.962% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -43.66% |
| Saniona AB (publ) | -95.81 Million SEK | 75.225% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 43.782% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -5319.405% |
| Xintela AB (publ) | -54.08 Million SEK | 56.11% |
| Amniotics AB (publ) | -30.87 Million SEK | 23.107% |
| Corline Biomedical AB | -1.8 Million SEK | -1212.161% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -44.756% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 80.712% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 86.653% |
| Intervacc AB (publ) | -102.85 Million SEK | 76.921% |
| Kancera AB (publ) | -64.88 Million SEK | 63.419% |
| Lipum AB (publ) | -37.17 Million SEK | 36.153% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -95.721% |
| Nanologica AB (publ) | -75.15 Million SEK | 68.417% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 92.366% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 93.885% |
| AcouSort AB (publ) | -17.08 Million SEK | -38.902% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 84.368% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 74.03% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 295.061% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -32.631% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 86.788% |
| Simris Alg AB (publ) | -37.3 Million SEK | 36.37% |
| Ziccum AB (publ) | -21.41 Million SEK | -10.858% |
| SynAct Pharma AB | -215.81 Million SEK | 89.001% |
| OncoZenge AB (publ) | -15.9 Million SEK | -49.27% |
| Camurus AB (publ) | 431.44 Million SEK | 105.502% |
| 2cureX AB (publ) | -32.51 Million SEK | 27.004% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -85.04% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 35.969% |
| I-Tech AB | 20.2 Million SEK | 217.492% |
| Cyxone AB (publ) | -22.98 Million SEK | -3.254% |
| Biosergen AB | -27.03 Million SEK | 12.206% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 46.118% |
| Alzinova AB (publ) | -16.48 Million SEK | -44.035% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 90.471% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 79.054% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -139.043% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 78.28% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -103.262% |